Alvotech’s AVT02 (a proposed biosimilar to Humira) Receives CHMP’s Positive Opinion for the Treatment of Autoimmune Diseases

Shots:

• The EMA’s CHMP has recommended the approval of Alvotech‘s AVT02 (100 mg/mL), a proposed biosimilar to Humira (adalimumab)  to treat AD in the EU
• The EC has been assigned to discuss the marketing authorization for AVT02. If approved, AVT02 will be extended to all EU member states along with other countries in the EEA, Iceland, Liechtenstein, and Norway
• Adalimumab is used to treat certain inflammatory conditions. Alvotech’s pipeline contains several mAb and fusion-protein biosimilar candidates that focus on autoimmunity, oncology, and inflammatory conditions to improve QoL for patients globally

Click here to­ read full press release/ article | Ref:  Businesswire  | Image: Businesswire